GSK Unveils Update On H1N1 Influenza Vaccine
Company has started clinical development program for its adjuvanted pandemic vaccine
GSK has issued an update on its progress to develop a vaccine against the Pandemic (H1N1) 2009 influenza virus. The company has also commenced the clinical development program for its adjuvanted pandemic vaccine.
Reportedly, the first clinical trial being conducted in Germany, will assess the use of the vaccine in healthy adults. Initial data is expected to be available for sharing with regulatory authorities in September.
Further trials of the Pandemic (H1N1) 2009 adjuvanted vaccine covering infants, children, adults and the elderly will commence over the coming weeks across Europe, Canada and the US.
The company said that the clinical development program, which has been designed in close partnership with regulatory authorities, will evaluate the immune response as well as tolerability and other safety aspects of the vaccine.
Thomas Breuer, head of Global Clinical R&D and CMO of GSK Biologicals, said: “GSK is making good progress with the development of its pandemic vaccine. Enrolment into the first study has been completed and in total, GSK will conduct 16 clinical trials of its pandemic vaccine in over 9000 individuals across Europe, Canada and the US. We continue to work closely with regulators and governments to assess and develop this vaccine.”
Related Insight
Suppliers Directory
LORENZ - Life Sciences Group
LORENZ is the most established provider of e-regulatory software and services in the world. Since 1989, LORENZ has focused exclusively on bringing intuitive, business-driven solutions to the market.
Suppliers
Congenix - Contract Research Services
Congenix is a regional contract research organization offering its clients a full range of services, covering the strategic development of clinical programs for all phases (I-IV) in the Russian Federation and Commonwealth of Independent States. Our project managers and monitors expertise at the local level will guide you through the logistics of identifying best sites and investigators for your studies, understanding local regulations and offer direct contact with key opinion leaders on your clinical development plan. In order to demonstrate our expertise and the real potential of our region, we offer protocol specific assessments in Russia and neighboring countries to sponsors at no cost.
Suppliers
Reading Scientific Services Ltd (RSSL) - Customer Driven, Science Led, Results Focused
RSSL is an independent global leader at the forefront of scientific analysis, consultancy, and training, serving the pharmaceutical, healthcare, biopharmaceutical, food, drink and consumer goods industries.
Suppliers
Biognosys - Targeted Proteomics Research Solutions & Tools
Biognosys is a Swiss proteomics company dedicated to the development of targeted proteomics services and tools. We use scheduled multiple reaction monitoring (MRM) to measure and quantify proteins from any species in any biological matrix. Our patented technology allows us to develop and validate MRM assays for new protein targets within 4 to 6 weeks with unprecedented efficiency. This approach not only accelerates biomarker or drug target discovery but also enables high-throughput protein measurement of drug response in complex samples.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
SAS® Drug Development
Published by Celerion
White Papers
Efficacy and Surgical Research Services (ESRS)
Published by Toxikon Europe
Contract Research & Services > Contract Research > White Papers
Pressure Mounts for Patient Access to Investigational Drugs
Published by CenterWatch
White Papers
Pharmacovigilance Services
Published by DOKUMEDS
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.